SCHEMBL427660

SCHEMBL427660

CC1(C)COCN1C(=O)n1nnc2c(F)cc(F)cc21

nearest known ligand 0.38

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 4/20 0.35
CNR1 P21554 1/20 0.35
KDM4E B2RXH2 3/20 0.31
ALDH1A1 P00352 3/20 0.31
GAA P10253 3/20 0.31
CYP1A2 P05177 2/20 0.31
HPGD P15428 2/20 0.31
HSD17B10 Q99714 2/20 0.31
GLA P06280 2/20 0.31
SMN1; SMN2 Q16637 2/20 0.31
CYP2C9 P11712 1/20 0.31
TSHR P16473 1/20 0.31
CASP1 P29466 1/20 0.31
CASP7 P55210 1/20 0.31
POLB P06746 1/20 0.31
CYP2C19 P33261 1/20 0.31
GRM5 P41594 1/20 0.31
RAB9A P51151 1/20 0.30
RXFP1 Q9HBX9 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL424712 0.76 CNR2 (0.33) CNR2KDM4EALDH1A1GAAHSD17B10
SCHEMBL425936 0.75 KCNMA1 (0.39) CNR2CNR1KDM4EALDH1A1GAA
SCHEMBL425578 0.74 FAAH (0.47) KDM4EALDH1A1GAAHPGDHSD17B10
SCHEMBL444826 0.73 CNR2 (0.35) CNR2CNR1KDM4EALDH1A1GAA
SCHEMBL427992 0.73 F12 (0.37) CNR2KDM4EALDH1A1GAACYP1A2
SCHEMBL427663 0.73 FAAH (0.36) CNR2CNR1KDM4EALDH1A1GAA
SCHEMBL425937 0.73 KCNMA1 (0.51) CNR2ALDH1A1HPGDSMN1; SMN2TSHR
SCHEMBL424826 0.72 HCAR3 (0.49) HPGD
SCHEMBL444875 0.72 HCAR3 (0.40) GAAHPGD
SCHEMBL7898107 0.72 KCNMA1 (0.43) CNR2CNR1KDM4EALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9353082-B2 Pharmaceutical compounds BIAL—PORTELA & CA, S.A. (PT) 2016-05-31 US disclosed
US-9353082-B2 Pharmaceutical compounds BIAL—PORTELA & CA, S.A. (PT) 2016-05-31 US disclosed
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & Cª, S.A. (PT) 2012-03-15 US disclosed
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & Cª, S.A. (PT) 2012-03-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS FAAH, FAAH2, ASAH1 CNR2 9/4885CNR1 15/4885KDM4E 1982/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.